Healthcare / Drug Manufacturers - GeneralShenzhen
$12.15
+0.47 (+4.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $130.4M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.9B
P/E
13.7x
↓EV/EBITDA
6.7x
↓ROE
9.8%
↑Gross Margin
7.0%
↓Debt/Equity
0.67
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.2%
FCF CAGR
-25.3%
FCF margin
0.4%
FCF / Net income
0.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $33.68B · net income $501.2M · FCF $118.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $33.68B | $33.68B | $33.35B | $32.05B | $30.62B |
| Net Income | $501.2M | $501.2M | $525.5M | $488.7M | $212.4M |
| EBITDA | $1.19B | $1.19B | $1.15B | $1.13B | $933.1M |
| EPS | 0.94 | 0.94 | 0.96 | 1.03 | 0.65 |
| Gross Margin | 7.0% | 7.0% | 6.9% | 6.8% | 6.5% |
| Operating Margin | 3.0% | 3.0% | 2.9% | 2.8% | 2.6% |
| Net Margin | 1.5% | 1.5% | 1.6% | 1.5% | 0.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.67 | 0.67 | 0.55 | 0.60 | 0.95 |
| Current Ratio | 1.35 | 1.35 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $118.5M | $118.5M | $130.4M | $257.0M | $283.8M |
| Returns | |||||
| ROE | 9.8% | 9.8% | 11.3% | 11.5% | 10.2% |
| Valuation | |||||
| P/E | 13.65 | 13.65 | 10.29 | 10.97 | 17.89 |
| EV/EBITDA | 6.66 | 6.66 | 5.52 | 5.56 | 5.27 |
| P/B | 1.27 | 1.27 | 1.17 | 1.26 | 1.83 |
| Growth & Yield | |||||
| Revenue Growth | 1.0% | 1.0% | 4.1% | 4.7% | — |
| EPS Growth | -2.1% | -2.1% | -6.8% | 58.5% | — |
| Dividend Yield | 3.1% | 3.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
4.7%
EPS terminal req.
$1.08
Spread vs growth
-6.8%
5Y implied EPS CAGR
6.8%
EPS terminal req.
$1.30
Spread vs growth
-8.9%
10Y implied EPS CAGR
8.4%
EPS terminal req.
$2.10
Spread vs growth
-10.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+15.4%
Start / end P/E
11.3x → 12.9x
EPS bridge
0.96 → 0.94
Residual
-0.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.